Why NewLink Genetics Is Soaring 37.5% Higher Today

After NewLink Genetics Corporation (NASDAQ: NLNK) updated data from its ongoing phase 2 trial of IDO inhibitor indoximod in advanced melanoma, shares in the immuno-oncology specialist shot higher yesterday. The news prompted a wave of positive comments from industry watchers, and as a result, on Friday shares are up an additional 37.5% at noon EDT.

NewLink Genetics' rally over the past two days has made up all the ground shares had lost earlier this summer when indoximod failed in a mid-stage breast cancer trial and former collaborator Roche Holdings jumped ship on GDC-0919, a second-generation IDO inhibitor that put up lackluster efficacy in trials.